GET DAILY SIGNALSQuoin Pharmaceuticals (QNRX) Reports Q3 Results with Clinical Progress and Financing Update
Key Takeaways
- Quoin Pharmaceuticals reported a net loss of approximately $4.9 million for the third quarter ended September 30, 2026, compared with roughly $3.9 million in the prior-year period.
- GAAP earnings per share came in at a loss of $0.97, narrower than the consensus estimate, which ranged around $1.53 to $1.88 per share.
- The company held approximately $33.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
- Quoin reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton Syndrome, with primary and key secondary endpoints achieving statistical significance.
- The company announced a private placement financing of up to $50.0 million with a healthcare-focused investor.
- For the nine months ended September 30, 2026, the net loss was approximately $15.2 million, versus $11.5 million in the same period of 2025.
Putting the Quarter in Context
As a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, Quoin Pharmaceuticals (QNRX) does not yet generate product revenue. Its quarterly results therefore receive more attention for cash position, spending trajectory, and clinical momentum than for any top-line figures. For a pre-revenue biotech, the market tends to focus on whether the company has sufficient runway to advance its lead candidates, particularly QRX003 for Netherton Syndrome and QRX009. The third quarter of 2026 carried extra weight because it aligned with a key clinical readout and a new financing announcement. I was watching closely to see whether the company could extend its cash runway while also delivering clinical data strong enough to support its development strategy.
The Reported Numbers
For the third quarter ended September 30, 2026, Quoin Pharmaceuticals (QNRX) reported a net loss of approximately $4.9 million, compared with roughly $3.9 million in the same quarter a year earlier. The company posted a GAAP loss of $0.97 per share, which came in narrower than the consensus estimate range of about $1.53 to $1.88 per share. For the first nine months of 2026, the net loss totaled approximately $15.2 million, up from $11.5 million in the comparable 2025 period, reflecting increased investment in research and development.
Quoin Pharmaceuticals (QNRX) ended the quarter with approximately $33.2 million in cash, cash equivalents, and marketable securities. The company also announced a private placement financing of up to $50.0 million with a healthcare-focused investor, a move aimed at strengthening its balance sheet. Separately, it reported positive interim data from its Phase 2/3 study of QRX003 in Netherton Syndrome, noting that primary and key secondary endpoints achieved statistical significance versus a pre-specified alpha-adjusted target. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Because Quoin Pharmaceuticals (QNRX) is a clinical-stage company, sentiment around its earnings tends to be driven by clinical and financing news rather than the income statement alone. Heading into the report, the stock had been volatile. The announcement of positive interim Phase 2/3 data for QRX003, combined with the up to $50.0 million private placement, provided a catalyst beyond the headline loss. A narrower-than-expected per-share loss also helped ease concerns about near-term cash burn. In my view, the combination of encouraging clinical progress, an expanded financing runway, and a smaller loss than anticipated positioned the quarter as a broadly constructive update for a company still years away from potential commercialization.
What to Watch Going Forward
Looking ahead, investors will likely focus on the durability of the QRX003 clinical data and the company’s path toward regulatory engagement in Netherton Syndrome. Additional interim or final data from the ongoing Phase 2/3 study will remain a central catalyst, as will any guidance on timing for discussions with regulators. Financing execution is another key variable. The announced private placement of up to $50.0 million, together with the roughly $33.2 million cash balance at quarter-end, should help clarify how far the company can extend its runway while funding multiple programs. Investors will also watch spending on research and development, which has been rising alongside expanded clinical activity. Beyond Netherton Syndrome, Quoin Pharmaceuticals (QNRX) has signaled plans to broaden QRX003’s reach, including a Fast Track designation received for Peeling Skin Syndrome and investigator-led studies across additional indications. Progress on the QRX009 platform and any new regulatory milestones, such as Investigational New Drug submissions, could further shape sentiment. Clinical trial outcomes, dilution risk from future financings, and the pace of cash consumption remain the factors most likely to influence the narrative in the quarters ahead.
Using AI Tools in My Research
In my own analysis workflow, I frequently rely on Tickeron’s AI Screener to quickly compare pre-revenue biotech names against peers on metrics like momentum, volatility, and sector activity. The platform’s customizable filters help surface relevant trade ideas and valuation signals without replacing my own fundamental review. It has become a useful complement when evaluating companies like Quoin Pharmaceuticals (QNRX) that are still in the development stage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for QNRX turns negative, indicating new downward trend
QNRX saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 72 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for QNRX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QNRX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QNRX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QNRX's RSI Indicator exited the oversold zone, 40 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for QNRX just turned positive on October 23, 2026. Looking at past instances where QNRX's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
Following a +3.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where QNRX advanced for three days, in 176 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.941) is normal, around the industry mean (2.904). P/E Ratio (-0.670) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. QNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biological products for cellular therapies
Industry Biotechnology
Advertisement